Literature DB >> 31597756

An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer.

Yin Wu1,2,3,4, Fernanda Kyle-Cezar1,2, Richard T Woolf1,5, Cristina Naceur-Lombardelli6, Julie Owen6, Dhruva Biswas4,7, Anna Lorenc1, Pierre Vantourout1,2, Patrycja Gazinska3,8, Anita Grigoriadis3, Andrew Tutt3,8, Adrian Hayday9,2.   

Abstract

Innate-like tissue-resident γδ T cell compartments capable of protecting against carcinogenesis are well established in mice. Conversely, the degree to which they exist in humans, their potential properties, and their contributions to host benefit are mostly unresolved. Here, we demonstrate that healthy human breast harbors a distinct γδ T cell compartment, primarily expressing T cell receptor (TCR) Vδ1 chains, by comparison to Vδ2 chains that predominate in peripheral blood. Breast-resident Vδ1+ cells were functionally skewed toward cytolysis and IFN-γ production, but not IL-17, which has been linked with inflammatory pathologies. Breast-resident Vδ1+ cells could be activated innately via the NKG2D receptor, whereas neighboring CD8+ αβ T cells required TCR signaling. A comparable population of Vδ1+ cells was found in human breast tumors, and when paired tumor and nonmalignant samples from 11 patients with triple-negative breast cancer were analyzed, progression-free and overall survival correlated with Vδ1+ cell representation, but not with either total γδ T cells or Vδ2+ T cells. As expected, progression-free survival also correlated with αβ TCRs. However, whereas in most cases TCRαβ repertoires focused, typical of antigen-specific responses, this was not observed for Vδ1+ cells, consistent with their innate-like responsiveness. Thus, maximal patient benefit may accrue from the collaboration of innate-like responses mounted by tissue-resident Vδ1+ compartments and adaptive responses mounted by αβ T cells.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31597756      PMCID: PMC6877350          DOI: 10.1126/scitranslmed.aax9364

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  87 in total

1.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

2.  IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Authors:  Mark Ayers; Jared Lunceford; Michael Nebozhyn; Erin Murphy; Andrey Loboda; David R Kaufman; Andrew Albright; Jonathan D Cheng; S Peter Kang; Veena Shankaran; Sarina A Piha-Paul; Jennifer Yearley; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan
Journal:  J Clin Invest       Date:  2017-06-26       Impact factor: 14.808

3.  Differential distribution of T lymphocyte subpopulations in the bovine mammary gland during lactation.

Authors:  T Yamaguchi; M Hiratsuka; K Asai; K Kai; K Kumagai
Journal:  J Dairy Sci       Date:  1999-07       Impact factor: 4.034

4.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

5.  Peripheral selection of antigen receptor junctional features in a major human gamma delta subset.

Authors:  F Davodeau; M A Peyrat; M M Hallet; I Houde; H Vie; M Bonneville
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

6.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

7.  Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway.

Authors:  Pierre Vantourout; Carrie Willcox; Andrea Turner; Chad M Swanson; Yasmin Haque; Olga Sobolev; Anita Grigoriadis; Andrew Tutt; Adrian Hayday
Journal:  Sci Transl Med       Date:  2014-04-09       Impact factor: 17.956

8.  Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.

Authors:  Laurence Buisseret; Soizic Garaud; Alexandre de Wind; Gert Van den Eynden; Anais Boisson; Cinzia Solinas; Chunyan Gu-Trantien; Céline Naveaux; Jean-Nicolas Lodewyckx; Hugues Duvillier; Ligia Craciun; Isabelle Veys; Denis Larsimont; Martine Piccart-Gebhart; John Stagg; Christos Sotiriou; Karen Willard-Gallo
Journal:  Oncoimmunology       Date:  2016-12-14       Impact factor: 8.110

9.  Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells.

Authors:  Hans-Jürgen Gober; Magdalena Kistowska; Lena Angman; Paul Jenö; Lucia Mori; Gennaro De Libero
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

10.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.

Authors:  Nicholas McGranahan; Rachel Rosenthal; Crispin T Hiley; Andrew J Rowan; Thomas B K Watkins; Gareth A Wilson; Nicolai J Birkbak; Selvaraju Veeriah; Peter Van Loo; Javier Herrero; Charles Swanton
Journal:  Cell       Date:  2017-10-26       Impact factor: 41.582

View more
  38 in total

1.  Distinct and temporary-restricted epigenetic mechanisms regulate human αβ and γδ T cell development.

Authors:  Juliette Roels; Anna Kuchmiy; Matthias De Decker; Steven Strubbe; Marieke Lavaert; Kai Ling Liang; Georges Leclercq; Bart Vandekerckhove; Filip Van Nieuwerburgh; Pieter Van Vlierberghe; Tom Taghon
Journal:  Nat Immunol       Date:  2020-07-27       Impact factor: 25.606

2.  TCR-Vγδ usage distinguishes protumor from antitumor intestinal γδ T cell subsets.

Authors:  Bernardo S Reis; Patrick W Darcy; Iasha Z Khan; Christine S Moon; Adam E Kornberg; Vanessa S Schneider; Yelina Alvarez; Olawale Eleso; Caixia Zhu; Marina Schernthanner; Ainsley Lockhart; Aubrey Reed; Juliana Bortolatto; Tiago B R Castro; Angelina M Bilate; Sergei Grivennikov; Arnold S Han; Daniel Mucida
Journal:  Science       Date:  2022-07-14       Impact factor: 63.714

3.  Repeated Plasmodium falciparum infection in humans drives the clonal expansion of an adaptive γδ T cell repertoire.

Authors:  Anouk von Borstel; Priyanka Chevour; Daniel Arsovski; Jelte M M Krol; Lauren J Howson; Andrea A Berry; Cheryl L Day; Paul Ogongo; Joel D Ernst; Effie Y H Nomicos; Justin A Boddey; Edward M Giles; Jamie Rossjohn; Boubacar Traore; Kirsten E Lyke; Kim C Williamson; Peter D Crompton; Martin S Davey
Journal:  Sci Transl Med       Date:  2021-12-01       Impact factor: 19.319

Review 4.  A multilayered immune system through the lens of unconventional T cells.

Authors:  Toufic Mayassi; Luis B Barreiro; Jamie Rossjohn; Bana Jabri
Journal:  Nature       Date:  2021-07-21       Impact factor: 49.962

Review 5.  Impact of cancer evolution on immune surveillance and checkpoint inhibitor response.

Authors:  Yin Wu; Dhruva Biswas; Charles Swanton
Journal:  Semin Cancer Biol       Date:  2021-02-22       Impact factor: 17.012

6.  Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers.

Authors:  Ghita Chabab; Florence Boissière-Michot; Caroline Mollevi; Jeanne Ramos; Evelyne Lopez-Crapez; Pierre-Emmanuel Colombo; William Jacot; Nathalie Bonnefoy; Virginie Lafont
Journal:  Cells       Date:  2020-06-24       Impact factor: 6.600

7.  Bibliometrics Analysis of Butyrophilins as Immune Regulators [1992-2019] and Implications for Cancer Prognosis.

Authors:  Yixi Wang; Na Zhao; Xianwen Zhang; Zhenhua Li; Zheng Liang; Jinrong Yang; Xingyu Liu; Yangzhe Wu; Kebing Chen; Yunfei Gao; Zhinan Yin; Xuejia Lin; Haibo Zhou; Dongbo Tian; Yang Cao; Jianlei Hao
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

Review 8.  Human γδ TCR Repertoires in Health and Disease.

Authors:  Alina Suzann Fichtner; Sarina Ravens; Immo Prinz
Journal:  Cells       Date:  2020-03-26       Impact factor: 6.600

Review 9.  The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.

Authors:  Yuxia Liu; Cai Zhang
Journal:  Cells       Date:  2020-05-13       Impact factor: 6.600

Review 10.  Recent advances in understanding the development and function of γδ T cells.

Authors:  Alejandra V Contreras; David L Wiest
Journal:  F1000Res       Date:  2020-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.